Kōbe-shi, Japan
Kōbe-shi, Japan

Time filter

Source Type

Experimental model could be instrumental in testing novel therapies for diseases that now lack treatments WASHINGTON - An off-the-shelf dietary supplement available for pennies per dose demonstrated the ability to reverse cellular damage linked to specific genetic mutations in transgenic fruit flies, an experimental model of genetic mutation-induced renal cell injury that features striking similarities to humans, a Children's National Health System research team reports April 20 in Journal of the American Society of Nephrology. "Transgenic Drosophila that carry mutations in this critical pathway are a clinically relevant model to shed light on the genetic mutations that underlie severe kidney disease in humans, and they could be instrumental for testing novel therapies for rare diseases, such as focal segmental glomerulosclerosis (FSGS), that currently lack treatment options," says Zhe Han, Ph.D., principal investigator and associate professor in the Center for Cancer & Immunology Research at Children's National and senior study author. Nephrotic syndrome (NS) is a cluster of symptoms that signal kidney damage, including excess protein in the urine, low protein levels in blood, swelling and elevated cholesterol. The version of NS that is resistant to steroids is a major cause of end stage renal disease. Of more than 40 genes that cause genetic kidney disease, the research team concentrated on mutations in genes involved in the biosynthesis of Coenzyme Q10 (CoQ10), an important antioxidant that protects the cell against damage from reactive oxygen. "This represents a benchmark for precision medicine," Han adds. "Our gene-replacement approach silenced the fly homolog in the tissue of interest - here, the kidney cells - and provided a human gene to supply the silenced function. When we use a human gene carrying a mutation from a patient for this assay, we can discover precisely how a specific mutation - in many cases only a single amino acid change - might lead to severe disease. We can then use this personalized fly model, carrying a patient-derived mutation, to perform drug testing and screening to find and test potential treatments. This is how I envision using the fruit fly to facilitate precision medicine." Drosophila pericardial nephrocytes perform renal cell functions including filtering of hemolymph (the fly's version of blood), recycling of low molecular weight proteins and sequestration of filtered toxins. Nephrocytes closely resemble, in structure and function, the podocytes of the human kidney. The research team tailor-made a Drosophila model to perform the first systematic in vivo study to assess the roles of CoQ10 pathway genes in renal cell health and kidney function. One by one, they silenced the function of all CoQ genes in nephrocytes. As any individual gene's function was silenced, fruit flies died prematurely. But silencing three specific genes in the pathway associated with NS in humans - Coq2, Coq6 and Coq8 - resulted in abnormal localization of slit diaphragm structures, the most important of the kidney's three filtration layers; collapse of membrane channel networks surrounding the cell; and increased numbers of abnormal mitochondria with deformed inner membrane structure. The flies also experienced a nearly three-fold increase in levels of reactive oxygen, which the study authors say is a sufficient degree of oxidative stress to cause cellular injury and to impair function - especially to the mitochondrial inner membrane. Cells rely on properly functioning mitochondria, the cell's powerhouse, to convert energy from food into a useful form. Impaired mitochondrial structure is linked to pathogenic kidney disease. The research team was able to "rescue" phenotypes caused by silencing the fly CoQ2 gene by providing nephrocytes with a normal human CoQ2 gene, as well as by providing flies with Q10, a readily available dietary supplement. Conversely, a mutant human CoQ2 gene from an patient with FSGS failed to rescue, providing evidence in support of that particular CoQ2 gene mutation causing the FSGS. The finding also indicated that the patient could benefit from Q10 supplementation. Video: Using the Drosophila model to learn more about disease in humans Paper: A Personalized Model of COQ2 Nephropathy Rescued by the Wild-Type COQ2 Allele or Dietary Coenzyme Q10 Supplementation


This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics is important in the application of biotechnology to manage genetic disorders and improve animal breeding. Genomics, proteomics and bioinformatics are also being applied to animal biotechnology. Transgenic technologies are used for improving milk production and the meat in farm animals as well as for creating models of human diseases. Transgenic animals are used for the production of proteins for human medical use. Biotechnology is applied to facilitate xenotransplantation from animals to humans. Genetic engineering is done in farm animals and nuclear transfer technology has become an important and preferred method for cloning animals.There is discussion of in vitro meat production by culture. Biotechnology has potential applications in the management of several animal diseases such as foot-and-mouth disease, classical swine fever, avian flu and bovine spongiform encephalopathy. The most important biotechnology-based products consist of vaccines, particularly genetically engineered or DNA vaccines. Gene therapy for diseases of pet animals is a fast developing area because many of the technologies used in clinical trials humans were developed in animals and many of the diseases of cats and dogs are similar to those in humans.RNA interference technology is now being applied for research in veterinary medicine. Molecular diagnosis is assuming an important place in veterinary practice. Polymerase chain reaction and its modifications are considered to be important. Fluorescent in situ hybridization and enzyme-linked immunosorbent assays are also widely used. Newer biochip-based technologies and biosensors are also finding their way in veterinary diagnostics. Approximately 124 companies have been identified to be involved in animal biotechnology and are profiled in the report. These are a mix of animal healthcare companies and biotechnology companies. Top companies in this area are identified and ranked. Information is given about the research activities of 11 veterinary and livestock research institutes. Important 108 collaborations in this area are shown. Share of biotechnology-based products and services in 2016 is analyzed and the market is projected to 2026. The text is supplemented with 35 tables and 5 figures.Selected 260 references from the literature are appended. Executive Summary 1. Introduction to Animal Biotechnology 2. Application of Biotechnology in Animals 3. A Biotechnology Perspective of Animals Diseases 4. Molecular Diagnostics in Animals 5. Biotechnology-based Veterinary Medicine 6. Research in Animal Biotechnology 7. Animal Biotechnology Markets 8. Regulatory issues 9. Companies Involved in Animal Biotechnology 10. References For more information about this report visit http://www.researchandmarkets.com/research/mdr33b/animal Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/animal-biotechnology-technologies-markets-and-companies-2016-2026-with-profiles-of-the-top-companies---research-and-markets-300452977.html


Global Agricultural Biotechnology market is accounted for $20.08 billion in 2015 and is expected to reach $39.5 billion by 2022 growing at a CAGR of 10.1% from 2015 to 2022. Factors stimulating the market growth are increasing demand for food, growing area of biotech crops, rising demand for biofuels & bio plastic production and demand for animal feed. Furthermore, increased investments and capital inflow for industry participants and research & development within Africa and Asia Pacific region will provide more growth prospects towards the market. However, stringent government rules and unacceptability of genetically modified crops will hinder market growth. Transgenic seeds and synthetic biology-enabled products will be the largest segment of the agricultural biotechnology application market. Soybean is anticipated to dominate the transgenic crops segment. North America commanded the regional market owing to increasing genetically modified crop cultivation. Asia Pacific is the fastest growing market due to large scale consumption for food, fiber, feed, and energy production. Some of the key players in global Agricultural Biotechnology market are ABBA GAIA S.L., Affymetrix Inc., Arcadia Biosciences Inc., Quinvita Nv, Bayer Cropscience Ag, Biocentury Transgene Co. Ltd., Rosetta Green, Eurofins Genescan Ag, Cofactor Genomics, Cellectis Plant Sciences, Edenspace Systems Corporation, Douglas Scientific, Dow Chemical Company, Dr. Chip Biotech Inc., Evogene Ltd., Insectigen Inc., Mendel Biotechnology Inc., Metabolix Inc., Plant Biosciences Ltd., Synthetic Genomics Inc., Targeted Growth Inc. and Vilmorin & Cie Sa. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt 4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements For more information, please visit https://www.wiseguyreports.com/sample-request/959894-agricultural-biotechnology-global-market-outlook-2016-2022


— Global Canola Oil Industry Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight. Companies profiled in this report are Louis Dreyfus Company, ADM, Cargill, Bunge, Richardson Oilseed, Viterra, Al Ghurair, CHS, Pacific Coast Canola (PCC), Oliyar, Wilmar International, COFCO, Chinatex Corporation, Maple Grain and Oil Industry, HSGC, Zhongsheng in terms of Basic Information, Manufacturing Base, Sales Area and Its Competitors, Sales, Revenue, Price and Gross Margin (2012-2017). Split by Product Types, with sales, revenue, price, market share of each type, can be divided into • Cold-pressed Canola Oil • Extracted Canola Oil • Transgenic Canola Oil • Non-transgenic Canola Oil Split by applications, this report focuses on sales, market share and growth rate of Canola Oil in each application, can be divided into • Food Industry • Biofuels • Oleo Chemicals • Other Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/481957 Table of Content: 1 Canola Oil Market Overview 2 Global Canola Oil Sales, Revenue (Value) and Market Share by Manufacturers 3 Global Canola Oil Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 4 Global Canola Oil Manufacturers Profiles/Analysis 5 North America Canola Oil Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 6 Latin America Canola Oil Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 7 Europe Canola Oil Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 8 Asia-Pacific Canola Oil Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 9 Middle East and Africa Canola Oil Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 10 Canola Oil Manufacturing Cost Analysis 11 Industrial Chain, Sourcing Strategy and Downstream Buyers 12 Marketing Strategy Analysis, Distributors/Traders 13 Market Effect Factors Analysis 14 Global Canola Oil Market Forecast (2017-2022) 15 Research Findings and Conclusion 16 Appendix Inquire more for more details about this report at: https://www.themarketreports.com/report/ask-your-query/481957 For more information, please visit https://www.themarketreports.com/report/2017-2022-global-top-countries-canola-oil-market-report-779176333


Maruya J.,Nara Women's University | Maruya J.,Osaka University | Maruya J.,Transgenic Inc. | Saeki K.,Nara Women's University
Plant and Cell Physiology | Year: 2010

Establishment of rhizobiumlegume symbiosis requires a series of mutual authentication, which might involve bacterial evasion of host defense. One such evasion-related genes is Sinorhizobium meliloti bacA that is essential for bacteroid formation. BacA is a transmembrane protein highly similar to Escherichia coli SbmA, a predicted transporter, and has homologs even in animal pathogens, such as Brucella abortus in which the homolog contributes to effective survival in host macrophages. Despite such a significance in hostmicrobe interactions, studies on rhizobial BacA have been mostly performed with the Medicago-Sinorhizobium model system that forms indeterminate cylindrical nodules. Since Lotus japonicus-Mesorhizobium loti constitutes another model system that forms determinate globular nodules, we genetically analyzed the bacA homolog with the locus tag mlr7400 in M. loti MAFF303099. We found that the mlr7400-null mutant ML7400DK was able to establish quasi-healthy symbiosis with the Lotus plant with 5080 nitrogen-fixing capacity. This dispensability for symbiosis was in contrast to the indispensability of S. meliloti BacA for symbiosis. However, free-living phenotypes of ML7400DK paralleled those of known bacA mutants, i.e. ML7400DK showed decreased sensitivity to the antibiotics bleomycin and gentamicin as well as increased sensitivity to membrane-disturbing reagents such as SDS. Conservation of the free-living function between Mlr7400 protein and S. meliloti BacA was further confirmed by heterologous complementation experiments. Although simple introduction of mlr7400 into the S. meliloti bacA mutant did not increase the symbiotic capacity at all, a significant but marginal increase was obtained when mlr7400 was fused to the S. meliloti bacA promoter. These findings might indicate currently progressing evolutionary specialization among BacASbmA proteins. © 2010 The Author.


Araki Y.,Hiroshima University | Hamafuji T.,Transgenic Inc | Noguchi C.,Hiroshima University | Shimizu N.,Hiroshima University
PLoS ONE | Year: 2012

We previously found that plasmids bearing a mammalian replication initiation region (IR) and a nuclear matrix attachment region (MAR) efficiently initiate gene amplification and spontaneously increase their copy numbers in animal cells. In this study, this novel method was applied to the establishment of cells with high recombinant antibody production. The level of recombinant antibody expression was tightly correlated with the efficiency of plasmid amplification and the cytogenetic appearance of the amplified genes, and was strongly dependent on cell type. By using a widely used cell line for industrial protein production, CHO DG44, clones expressing very high levels of antibody were easily obtained. High-producer clones stably expressed the antibody over several months without eliciting changes in both the protein expression level and the cytogenetic appearance of the amplified genes. The integrity and reactivity of the protein produced by this method was fine. In serum-free suspension culture, the specific protein production rate in high-density cultures was 29.4 pg/cell/day. In conclusion, the IR/MAR gene amplification method is a novel and efficient platform for recombinant antibody production in mammalian cells, which rapidly and easily enables the establishment of stable high-producer cell clone. © 2012 Araki et al.


Patent
National Cancer Center and Trans Genic Inc. | Date: 2011-09-09

An antibody against mutant -actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of -actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.


Patent
Trans Genic Inc. and National Cancer Center | Date: 2014-07-16

An antibody against mutant -actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of -actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.


Patent
Trans Genic Inc. and Kumamoto University | Date: 2015-02-04

The present invention provides embryonic stem cells obtainable from an embryo of an immunodeficient mouse which is deficient in both Rag2 and Jak3 genes by culture in the presence of a GSK3 inhibitor and an MEK inhibitor, as well as a transgenic mouse, which is created with the use of these embryonic stem cells.


Patent
Trans Genic Inc. and Kumamoto University | Date: 2012-03-27

The present invention provides embryonic stem cells obtainable from an embryo of an immunodeficient mouse which is deficient in both Rag2 and Jak3 genes by culture in the presence of a GSK3 inhibitor and an MEK inhibitor, as well as a transgenic mouse, which is created with the use of these embryonic stem cells.

Loading Transgenic Inc. collaborators
Loading Transgenic Inc. collaborators